🔗 References (max. 100)
| part | subject | predicate | object | published by | date | |
|---|---|---|---|---|---|---|
|
Assertion
|
|
|||||
|
Assertion
|
Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers.
|
|
||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|